Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibod ...

BioNTech also laid off 63 employees in June in conjunction with the discontinuation of its cell therapy manufacturing ...

1 BNT327, formerly also known as PM8002, was initially jointly developed by BioNTech and Biotheus Inc (“Biotheus”). Since February 2025, Biotheus is a member of the BioNTech Group.

BNT327, BioNTech’ s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set ...

Continued execution of BioNTech’s oncology strategy with focus on two pan-tumor programs including two announced transactions: mRNA-based cancer immunotherapy candidates and BNT327, a bispecific antib ...

Truist rates BioNTech a Buy, citing its shift to oncology with BNT327 leading the way. Key data updates and growth catalysts are expected by 2025.

Newman’s confidence in BNT327’s prospects justifies his Buy rating on BioNTech SE’s stock. Newman covers the Healthcare sector, focusing on stocks such as Merus, Regeneron, and BioNTech SE.

“In the second quarter, we took significant steps to advance BioNTech into a multiproduct biotechnology company by ...

This study could significantly impact BioNTech’s stock performance and investor sentiment, especially if the results demonstrate a breakthrough in breast cancer treatment. The involvement of ...

BioNTech’s BNT327, a next-generation bispecific antibody candidate targeting PD-L1 and VEGF-A, is currently being evaluated in multiple ongoing trials with more than 1,000 patients treated to ...